Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on OCS stock, giving a Buy rating yesterday.
Jason Gerberry has given his Buy rating due to a combination of factors that highlight the potential of Oculis Holding’s ophthalmology portfolio. The recent completion of a $100 million equity financing extends the company’s cash runway into early 2028, providing financial stability to support ongoing and future developments. Additionally, the upcoming R&D Day is expected to shed light on pipeline advancements, particularly focusing on OCS-05, a neuroprotective candidate with promising phase 2 data showing improvements in retinal thickness and vision metrics.
Gerberry also notes that Oculis has received positive feedback from the FDA regarding its precision medicine approach for OCS-02, an anti-TNF α biologic eye drop for dry eye, which could differentiate it in the market. Furthermore, the phase 3 DIAMOND trials for OCS-01 in diabetic macular edema are on track, with data expected in the first half of 2026. These developments, along with the company’s strategic focus and underappreciated potential relative to peak sales, underpin Gerberry’s confidence in the stock’s future performance.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $35.00 price target.